Skip to content

Study · Observational study · 2019

4 results

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI

The oncologist24 Oct 2018Cited by 13 (Europe PMC)

PMID30355775 (opens in a new tab)PMCIDPMC6459235 (opens in a new tab)DOI10.1634/theoncologist.2018-0217 (opens in a new tab)PepBankPUB-30355775
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In nonprogressing NET patients with elevated baseline biomarkers, lanreotide reduced urinary 5-HIAA more than placebo.

    In plain wordsIn nonprogressing NET patients with elevated baseline biomarkers, lanreotide reduced urinary 5-HIAA more than placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseUrinary 5-HIAA reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Tumor Biomarkers · Cancer
    Studied dose
    120 mg every 28 days · deep subcutaneous · 96 weeksAs given in this study (human).

    Measurements

    P value for greater 5-HIAA reduction, lanreotide versus placebo
    < 0.05
    patients with baseline >ULN who did not progress

    Source sentences

    Summary
    Among patients with >ULN baseline values who did not progress after 96 weeks of treatment, significantly greater reductions in 5-HIAA and CgA were observed in lanreotide-treated versus placebo-treated patients throughout the study (all p < .05).
    1 context sentence
    Summary · context
    Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot/autogel 120 mg or placebo once every 28 days for 96 weeks.
  2. 02HumanObservational studyEfficacy outcome

    In nonprogressing NET patients with elevated baseline biomarkers, lanreotide reduced plasma CgA more than placebo.

    In plain wordsIn nonprogressing NET patients with elevated baseline biomarkers, lanreotide reduced plasma CgA more than placebo.

    Peptide
    Lanreotide
    Outcome
    DecreasePlasma CgA reduction
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Tumor Biomarkers · Cancer
    Studied dose
    120 mg every 28 days · deep subcutaneous · 96 weeksAs given in this study (human).

    Measurements

    P value for greater CgA reduction, lanreotide versus placebo
    < 0.05
    patients with baseline >ULN who did not progress

    Source sentences

    Summary
    Among patients with >ULN baseline values who did not progress after 96 weeks of treatment, significantly greater reductions in 5-HIAA and CgA were observed in lanreotide-treated versus placebo-treated patients throughout the study (all p < .05).
    1 context sentence
    Summary · context
    Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot/autogel 120 mg or placebo once every 28 days for 96 weeks.
  3. 03HumanObservational studyEfficacy outcome

    Among lanreotide-treated NET patients, 5-HIAA responders had longer PFS than nonresponders (p = .0071).

    In plain wordsAmong lanreotide-treated NET patients, 5-HIAA response was linked to longer survival without progression than no response.

    Peptide
    Lanreotide
    Outcome
    IncreasePFS by 5-HIAA response
    Study

    n: not reported in source

    Comparator
    Lanreotide-treated 5-HIAA nonresponders
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · deep subcutaneous · 96 weeksAs given in this study (human).

    Measurements

    P value for PFS, 5-HIAA responders versus nonresponders
    0.0071
    lanreotide-treated patients

    Source sentences

    Summary
    PFS was also significantly prolonged among lanreotide-treated 5-HIAA responders versus nonresponders (p = .0071) but was not significantly different among placebo-treated 5-HIAA responders versus nonresponders.
    1 context sentence
    Summary · context
    Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot/autogel 120 mg or placebo once every 28 days for 96 weeks.
  4. 04HumanObservational studyEfficacy outcome

    Among lanreotide-treated NET patients, PFS did not differ significantly between CgA responders and nonresponders.

    In plain wordsAmong lanreotide-treated NET patients, survival without progression did not differ significantly between CgA responders and nonresponders.

    Peptide
    Lanreotide
    Outcome
    No significant changePFS by CgA response
    Study

    n: not reported in source

    Comparator
    Lanreotide-treated CgA nonresponders
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · deep subcutaneous · 96 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in PFS between lanreotide-treated CgA responders versus nonresponders or between placebo-treated CgA responders versus nonresponders.
    1 context sentence
    Summary · context
    Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot/autogel 120 mg or placebo once every 28 days for 96 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.